Ultragenyx Pharmaceutical RARE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$185M-22.5% | -$128.56M+3.5% | -$180.41M-35.1% | -$114.95M+12.6% | -$151M+11.5% | ||
| $8M-11.1% | $8.79M-7.9% | $8.61M-1.7% | $8.61M-2.9% | $9M+1.8% | ||
| -$19M-90.0% | $33.83M+60.8% | -$5.43M— | $12.59M— | -$10M-140% | ||
| $4M+300% | —— | $5.6M+124% | —— | $1M-52.9% | ||
| -$1M-200% | —— | $273K-93.5% | $1.42M+233% | $1M+1,199% | ||
| —— | —— | —— | —— | —— | ||
| -$197M-18.7% | -$99.83M-25.9% | -$91.42M-36.5% | -$108.75M-41.3% | -$166M+13.0% | ||
| $1M0.0% | $938K+475% | $1.28M-21.0% | $2.78M+38.6% | $1M-68.9% | ||
| $131M— | $153.56M+841% | $16.94M-95.4% | $15.5M+360% | $0-100% | ||
| $88M-35.8% | -$143K— | —— | —— | $137M+4,715% | ||
| $5M-66.7% | —— | —— | —— | $15M+50.0% | ||
| $0-100% | —— | $185K-8.9% | $88K+115% | $1M-51.6% | ||
| -$49M-141% | —— | $117.18M+143% | $71.07M+17.3% | $120M+27.1% | ||
| -$1M-200% | —— | $294K— | $3.36M+619% | $1M+247% | ||
| -$247M-449% | $221.46M— | $26.06M+108% | $49.49M-86.5% | -$45M+53.6% | ||
| $1M-50.0% | $516K-83.8% | $704K-77.4% | $780K-73.5% | $2M-46.8% | ||
| $30M-25.0% | $37.29M-7.1% | $37.27M-10.4% | $38.45M-2.3% | $40M+8.3% | ||
| -$57M-18.8% | $37.01M-20.2% | $45.12M+317% | -$10.14M-140% | -$48M-35.1% | ||
| $9M-47.1% | $2.74M— | —— | $165K-97.6% | $17M+359% | ||
| $21M+50.0% | $19.47M+25.8% | $14.15M-10.0% | $14.04M-12.0% | $14M-11.7% | ||
| $20M+5.3% | $37.58M+11.9% | $24.91M+8.1% | $30.51M+16.0% | $19M+5.2% | ||
| -$1M-200% | —— | $273K-93.5% | $1.42M+233% | $1M+1,199% | ||
| $0-100% | —— | $185K-8.9% | $88K+115% | $1M-51.6% | ||
| $5M-66.7% | —— | —— | —— | $15M+50.0% | ||
| $88M-35.8% | $82.12M-31.2% | $135.59M+44.9% | $89.3M+30.7% | $137M+6.4% | ||
| -$1M-200% | —— | $294K— | $3.36M+619% | $1M+247% | ||
| -$198M-18.6% | -$100.77M-26.8% | -$92.7M-35.1% | -$111.53M-41.2% | -$167M+13.9% | ||
| -$198M-18.6% | -$100.77M-26.8% | -$92.7M-35.1% | -$111.53M-41.2% | -$167M+13.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ultragenyx Pharmaceutical's cash flow data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.